Finance Monthly CFO Awards 2019 Winners Edition

www.finance-monthly.com 56 Finance Monthly CFO Awards 2019 CFO at IMV Inc. PIERRE LABBÉ CPA, CA, ICD ABOUT PIERRE LABBÉ Pierre Labbé is Chief Financial Officer at IMV Inc. since February 2017 and has more than 25 years of financial leadership roles in various industries. Since his arrival at IMV, Pierre has led the completion of three public offerings, securing increasing amounts of $10, $14 and $29 million CAN of financing. He also played a decisive role in the listing of IMV’s shares on the Nasdaq Capital Market on June 2018. Pierre is a successful executive experienced in stimulating and structuring business growth in fast-changing environments. Before joining IMV, Pierre was Vice President andChief Financial Officer of Leddartech Inc., aworld leader in LIDAR for the automotive industry. His experience in the life sciences and pharmaceutical sector includes serving as CFO and secretary of Medicago Inc. until the completion its privatization following the acquisition by Mitsubishi Tanabe Pharma for an enterprise value of $357M CAN in 2013. In his career as a senior financial officer, he has participated in the development of strategic plans, financing, IPOs, and mergers and acquisitions (over $1 billion CAN in transactions). Pierre is also a Director of Osisko Gold Royalties Ltd. (TSX:OR – NYSE:OR) He holds a Bachelor’s Degree in Business Administration and a license in accounting from Université Laval, Québec City. Pierre is a member of Ordre des CPA du Québec, the CPA of Canada and the Institute of Corporate Directors. FIRM PROFILE IMV Inc. (NASDAQ:IMV - TSX:IMV ) is a clinical-stage biopharmaceutical company with a focus in Immuno-Oncology. IMV’s team is committed to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer. IMV is pioneering a new class of immunotherapies based on the company’s proprietary drug delivery platform (DPX). Designed to elicit a more rapid, robust, and sustained immune response, the no-release drug delivery platform enables the programming of immune cells in vivo. IMV’s lead program, DPX-Survivac, is a T cell-activating immunotherapy targeting survivin, an antigen present in more than 20 solid and hematological tumor types. To date, data from DPX-Survivac have exhibited a favorable safety profile and encouraging signs of anti-tumor activity. IMV is currently exploring this program in multiple ongoing trials, both as a single regimen in advanced ovarian cancer as well as a combination therapy in various clinical studies with Merck. CONTACT Pierre Labbé CPA, CA, ICD CFO at IMV Inc. www.imv-inc.com “IMV’s team is committed to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer.” Finance Monthly CFO Awards 2019 CANADA